Estramustine

6262 * 6272 Blocking of Collagenase Secretion by Estramustine during in Vitro Tumor Cell Invasion. Min Wang and Mark E. Stearns. limai Analysis of Untreated Non-Hodgkin's Lymphoma Utiliz ing Immunoglobulin Gene Rearrangement and Immunophenorype. Richard A. Rudders, Satinder Dhillon, and Theodore G. Krontiris. Proteases in Cyst Fluid from Human Gross Cyst Breast Disease. Leo Kesner, Wanshang Yu, H. Leon Bradlow, Charles W. Breed, and Martin Fleisher. Modulation of Plasminogen Activator Activity in Human Endometrial Adenocarcinoma Cells by Basic Fibroblast Growth Factor and Transforming Growth Factor Y. Marco Presta, Jeanette A. M. Maier, Marco Rusnati, David Moscatelli, and Giovanni Ragnotti. * 6424 Production of Growth Potentiating Factoids ; for Autologous Blast Cells by Acute Myeloblastic Leukemia Cells. Ikuo Murohashi, Kaoni Nagata, Toshiya Suzuki, Yoko Yamashita, Yasuo Maruyama, and Nobuo Nara. Insulin-like Growth Factor 1 Receptors in Human Breast Cancer and Their Relation to Estradiol and Progesterone Receptors. J-P. Peyrat, J. Bonneterre, R. Beuscart, J. Djiane, and A. Dmaille. Autocrine Production of Pre-B-Cell Stimulating Activity by a Va riety of Transformed Murine Pre-B-Cell Lines. FranoisM. Lemoine, Gerald Krystal, R. Keith Humphries, and Connie J. Eaves. Nuclear Fragmentation and Premature Chromosome Condensa tion Induced by Heat Shock in S-Phase Chinese Hamster Ovary Cells. Michael A. Mackey, William F. Morgan, and William C. Dewey. Loss of Metastatic and Primary Tumor Factor X Activator Capa bilities by Lewis Lung Carcinoma Cells Cultured in Vitamin K-dependent Protein Deficient Serum. Michael J. Fasco, George E. Eagan, Adrian C. Wilson, John F. Gierthy, and David L. Lincoln.

Recovery from inactivation. In contrast, substituting leucine for valine at position 1341 had diverse effects on single channel recordings that were anticipated from the reduced use-dependent block for diltiazem. These results are summarized in Table III. The longest open time was observed for the mutants HHT5411 6.45 0.6 ms, n 5 ; and HHT-5421 11.17 1.33 ms, n 7 ; , 123 and 261% of the wild type, respectively Table III, Fig. 5B ; . Thus, these mutants exhibited slowed inactivation from the open state Fig. 5B ; . These observations are also consistent with the data from the inactivation of macroscopic currents Table I ; . The average latencies to the first opening for all mutants was similar to that of the wild type, suggesting that these mutations have little effect on the activation process Fig. 5C.

K. 1956 ; . A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J. 62, 315-322. CASE, R. M. 1978 ; . Synthesis, intracellular transport and discharge of exportable proteins in the pancreatic acinar cell and other cells. Biol. Rev. 53, 211-354. I-SAN-LIN, R. & SCHJEIDE, O. A. 1969 ; . Micro estimation of RNA by the cupric ion catalysed orcinol reaction. Analyt. Biochem. 27, 473-483. KRAMER, M. F. & POORT, C. 1968 ; . Protein synthesis in the pancreas of the rat after stimulation of secretion. Z. Zellforsch. mikrosk. Anat. 86, 475-486. MANCHESTER, K. L. & WOOL, I. G. 1963 ; . Insulin and incorporation of amino acids into protein of muscle. 2. Accumulation and incorporation studies with the perfused rat heart. Biochem. J. 89, 202-209. MARTIN, T. E. 1973 ; . A simple general method to determine the proportion of active ribosomes in eukaryotic cells. Expl Cell Res. 80, 496-498. POORT, C. & KRAMER, M. F. 1969 ; . Effect of feeding on the protein synthesis in mammalian pancreas. Gastroenterology 57, 689-696. Received 20 November 1980.
Cytotoxic antitumor antibiotics anthracycline family : daunorubicin , doxorubicin , epirubicin , idarubicin , mitoxantrone , valrubicin ; - streptomyces actinomycin , bleomycin , mitomycin , plicamycin ; - hydroxyurea topoisomerase inhibitors camptotheca : camptothecin , topotecan , irinotecan ; , podophyllum : etoposide , teniposide ; ci monoclonal antibodies alemtuzumab , bevacizumab , cetuximab , gemtuzumab , panitumumab , rituximab , tositumomab , trastuzumab photosensitizers aminolevulinic acid , methyl aminolevulinate , porfimer sodium , verteporfin tyrosine kinase inhibitors dasatinib , erlotinib , gefitinib , imatinib , lapatinib , nilotinib , sorafenib , sunitinib other retinoids alitretinoin , tretinoin ; - altretamine , amsacrine , anagrelide , arsenic trioxide , asparaginase pegaspargase ; , bexarotene , bortezomib , denileukin diftitox , estramustine , masoprocol , mitotane humanized monoclonal antibodies cancer alemtuzumab , apolizumab , bevacizumab , bivatuzumab mertansine , cantuzumab mertansine , cidfusituzumab , cidtuzumab , dacetuzumab , etaracizumab , etaratuzumab , gemtuzumab ozogamicin , inotuzumab ozogamicin , labetuzumab , lintuzumab , matuzumab , nimotuzumab , pecfusituzumab , pectuzumab , pertuzumab , quartuzumab , sibrotuzumab , sontuzumab , tacatuzumab tetraxetan , trastuzumab , tucusituzumab pain ananeuzumab , anergrozumab , talineuzumab , taneuzumab , tanirazumab immunosuppression anrulizumab , aselizumab , atlizumab , azulizumab , balizumab , belizumab , cedelizumab , daclizumab , doraglizumab , dorlizumab , drinalizumab , durlizumab , efalizumab , epratuzumab , erlizumab , fontolizumab , hylizumab , ibalizumab , lebrilizumab , lucalizumab , mepolizumab , pascolizumab , pexelizumab , reslizumab , rovelizumab , ruplizumab , siplizumab , talizumab , teglizumab , teplizumab , tocilizumab , tolizumab , toralizumab , tralizumab , treglizumab , trelizumab , trilizumab , ubrelizumab , visilizumab , xalizumab , zulizumab viral infections felvizumab , nolovizumab , numavizumab , palivizumab , ralivizumab , reslivizumab , resyvizumab , umavizumab other bapineuzumab , certolizumab pegol , eculizumab , epkizumab , matenazumab , motavizumab , natalizumab , ocrelizumab , omalizumab , ranibizumab , tadocizumab , tefibazumab , tucotuzumab celmoleukin , urtoxazumab this entry is from wikipedia, the leading user-contributed encyclopedia. BEX TR A is registered trademark of Pharmacia Enterprises S.A., Pfizer Canada Inc, Licensee.

The dopamine D3 receptor is highly distributed in the nucleus accumbens, the terminal site of the mesolimbic dopaminergic system Sokoloff et al., 1990 ; . The limbic system-selective expression of the dopamine D3 receptor has led to particular interest in this receptor as a potential mediator of some of the psychoeffective functions of dopamine neurotransmission Levant, 1997 ; . Although pharmacological studies using dopamine D3 receptorpreferring agonists such as 7-OH-DPAT can generally support this view Caine and Koob, 1993 ; , the dubious selectivity of these agonists severely limits conclusions about the physiological functions of the dopamine D3 receptor. nock-out mice with dopamine D3 receptor gene deletions have been successfully developed by homologous recombination Accili et al., 1996; Xu et al., 1997 ; . The availability of transgenic dopamine D3 receptor knock-out mice allows us to determine the physiological function mediated via the dopamine D3 receptor and the interaction between -opioidergic system and dopamine D3 receptors. Using dopamine D3 receptor knock-out mice, we confirmed that a deletion of the dopamine D3 receptor had no effect on either dopamine D1 or D2 receptors, suggesting the utility of these mice for studying the distinct role of dopamine D3 receptors Narita et al., 2002a, b; the present study ; . In the present study, we found that the mutation of the dopamine D3 receptor resulted in no detectable change in the -opioid receptor in the brain. Furthermore, the elimination of dopamine D3 receptor expression in mutant mice failed to affect morphine-stimulated [ 35S]GTP S binding, indicating no significant change in the ability of the -opioid receptor-induced G-protein activation in this phenotype. These results suggest that deletion of the dopamine D3 receptor gene could not directly affect the -opioidergic function in the brain. Under the present condition, we investigated the morphineinduced rewarding effect in mice lacking dopamine D3 receptor. A significant place preference for drug-associated place was observed in the mutant mice at 0.56 mg kg morphine, whereas no preferences were seen in the wild-type mice at even 13 mg kg. This enhanced effect was completely reversed by intracerebro and etidronate.
Estramustine and estrone analogs rapidly and reversibly inhibit deoxyribonucleic acid synt jm piepmeier , dl keefe , ma weinstein , d yoshida , j zielinski , tt lin , z chen , f naftolin department of surgery, yale university school of medicine, new haven, conne estramustine is an estradiol-based agent that has been shown to accumulate in human glioma cells, resulting in a concentration-dependent alteration in cell size and shape within minutes and an inhibition of proliferation over 3 to 6 days. ', 250 ; onmouseout hideddrivetip ; cancer cells were xenografted to nude mice and treated with estramustine for 2 weeks and external radiation radiation therapy that uses a machine to aim high-energy rays at the cancer and etodolac.
Where dMa dt is the rate of absorption, AT is the total epithelial surface area of the perfused segment of intestine and Cr is the concentration of compound entering the intestine. The rate of absorption was calculated as Qm Cm R, where Qm is the blood flow rate over the collection period, Cm is the concentration of compound in mesenteric blood during that period and R is the blood-to-plasma concentration ratio of the compound. AT was calculated using the equation for the area of a cylinder AT 2 riLi ; , where Li is the length of the perfused segment of intestine and ri is the internal radius, 0.2 cm Kim 1996 ; . Given a value for the Papp, a theoretical oral intestinal bioavailability may be predicted mathematically using the following equation Lennernas 1995 ; : Fpred e 1 Papp intestinal surface area mean intestinal transit time intestinal volume.

Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166 1 ; : 63-7. Kattan MW, Scardino PT. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer 2002; 1 2 ; : 90-6. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337 5 ; : 295-300. Abbas F, Scardino PT. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol Clin North 1996; 23 4 ; : 587-604. Fair WR, Rabbani F, Bastar A, Betancourt J. Neoadjuvant Hormone Therapy Before Radical Prostatectomy: Update on the Memorial Sloan-Kettering Cancer Center Trials. Mol Urol 1999; 3 ; : 253-60. Klotz LH, Goldenberg SL, Jewett M, et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. Urology 1999; 53 4 ; : 757-63. Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002; 167 1 ; : 1126. Witjes WP, Schulman CC, Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997; 49 3A Suppl ; : 65-9. Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166 2 ; : 500-6; discussion 6-7. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17 8 ; : 2506-13. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19 9 ; : 250916. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14 6 ; : 175664. Eklov S, Nilsson S, Larson A, Bjork P, Hartley-Asp B. Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo. Prostate 1992; 20 1 ; : 43-50. Hartley-Asp B. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Prostate 1984; 5 1 ; : 93-100. Hartley-Asp B, Gunnarsson PO. Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line DU 145 ; . J Urol 1982; 127 4 ; : 818-22. Speicher LA, Laing N, Barone LR, Robbins JD, Seamon KB, Tew KD. Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. Mol Pharmacol 1994; 46 5 ; : 866-72 and exemestane.
Docetaxel and estramustine also showed differential effects on gene expression between mono- and combination treatment and estramustine. Prostate cancer is plagued with difficulty in defining endpoints for clinical trials. Given the long expected survival in this condition, it will be decades, if at all, before we know how best to use docetaxel in the settings enumerated above. We must use our individual judgment as community oncologists on how best to use docetaxel for patients who would have been excluded by the TAX 327 and SWOG 9916 entry criteria and not assume the absence of data as a surrogate for limiting usage. Certainly, enrollment in smaller clinical trials in these scenarios is preferable to the ad hoc usage of chemotherapy. As a community oncologist who only treats prostate cancer, I was simultaneously ecstatic about and saddened by the presentation of the above results--ecstatic to see an obviously beneficial treatment recommended widely and saddened to know that over the past 45 years, many men did not receive and still may not receive ; docetaxel because of the absence of so-called definitive trials. I personally fear that evidence-based medicine could become the "golden handcuffs" of medical treatment choices. In my own prostate-specific practice, I routinely recommend weekly docetaxel-based chemotherapy with both a short course of estramustine and the addition of weekly carboplatin, based on the data from the trials described above. The indications include metastatic AIPC, both with and without pain, as well as metastatic androgen-dependent prostate cancer. Docetaxel therapy is also recommended selectively for patients with adverse risk features, such as high Gleason scores, a PSA level 20 ng mL baseline, T3 tumors, or large tumor volume based on the number of positive biopsies. Whenever possible, this is best accomplished in the setting of a clinical trial but often is done "off study." Further, I frequently encounter patients in whom "standard" docetaxel therapy has failed, such as and exenatide.

Center, randomized, double-masked clinical trials.124, 125 CsA emulsion for treatment of KCS was subsequently evaluated in several large multicenter, randomized, doublemasked clinical trials. In a Phase 2 clinical trial, four concentrations of CsA 0.05%, 0.1%, 0.2%, or 0.4% ; administered twice daily to both eyes of 129 patients for 12 weeks was compared to vehicle treatment of 33 patients.126 CsA was found to significantly decrease conjunctival rose bengal staining, superficial punctate keratitis, and ocular irritation symptoms sandy or gritty feeling, dryness, and itching ; in a subset of 90 patients with moderate-to-severe KCS. There was no clear dose response; CsA 0.1% produced the most consistent improvement in objective endpoints, whereas CsA 0.05% gave the most consistent improvement in patient symptoms Level I ; . Two independent Phase 3 clinical trials compared twice-daily treatment with 0.05% or 0.1% CsA or vehicle in 877 patients with moderate-to-severe dry eye disease.127 When the results of the two Phase 3 trials were combined for statistical analysis, patients treated with CsA, 0.05% or 0.1%, showed significantly P 0.05 ; greater improvement in two objective signs of dry eye disease corneal fluorescein staining and anesthetized Schirmer test values ; compared to those treated with vehicle. An increased Schirmer test score was observed in 59% of patients treated with CsA, with 15% of patients having an increase of 10 mm more. In contrast, only 4% of vehicle-treated patients had this magnitude of change in their Schirmer test scores P 0.0001 ; . CsA 0.05% treatment also produced significantly greater improvements P 0.05 ; in three subjective measures of dry eye disease blurred vision symptoms, need for concomitant artificial tears, and the global response to treatment ; . No dose-response effect was noted. Both doses of CSA exhibited an excellent safety profile with no significant systemic or ocular adverse events, except for transient burning symptoms after instillation in 17% of patients. Burning was reported in 7% of patients receiving the vehicle. No CsA was detected in the blood of patients treated with topical CsA for 12 months. Clinical improvement from CsA that was observed in these trials was accompanied by improvement in other disease parameters. Treated eyes had an approximately 200% increase in conjunctival goblet cell density.128 Furthermore, there was decreased expression of immune activation markers ie, HLA-DR ; , apoptosis markers ie, Fas ; , and the inflammatory cytokine IL-6 by the conjunctival epithelial cells.129, 130The numbers of CD3-, CD4-, and CD8-positive T lymphocytes in the conjunctiva decreased in cyclosporine-treated eyes, whereas vehicle-treated eyes showed an increased number of cells expressing these markers.131 After treatment with 0.05% cyclosporine, there was a significant decrease in the number of cells expressing the lymphocyte activation markers CD11a and HLA-DR, indicating less activation of lymphocytes compared with vehicle-treated eyes. Two additional immunophilins, pimecrolimus and tacrolimus, have been evaluated in clinical trials of KCS. 10 Trade diversion growing out of a regional negotiation can reflect trade-offs from a process of endogenous protection which is essential for the political sustainability of commitments. Also, as mentioned earlier, in a "dynamic" setting some trade diversion could be a benefit to the extent it ultimately would contribute to lower costs, increase competitiveness and growth and exjade.